CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds

Journal of Investigative Dermatology

Volumn 111, Issue 6, 1998, Pages 1202-1206

  Fargnoli, Maria Concetta ^a   Chimenti, Sergio ^a   Keller, Gisela ^b   Soyer, Hans Peter ^c   Pozzo, Vera Dal ^d   Höfler, Heinz ^b   Peris, Ketty ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Cell cycle; Melanoma susceptibility gene

Indexed keywords

PROTEIN; PROTEIN P14ARF; CYCLIN DEPENDENT KINASE INHIBITOR;

ADULT; AGED; ARTICLE; FAMILY HEALTH; FEMALE; GENETIC VARIABILITY; GENETICS; HUMAN; MALE; MELANOMA; MIDDLE AGED; MUTATION; PEDIGREE; POINT MUTATION; TUMOR SUPPRESSOR GENE; ALTERNATIVE RNA SPLICING; CHROMOSOME 9P; FAMILIAL DISEASE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GERM LINE; MISSENSE MUTATION; MULTIGENE FAMILY; PRIORITY JOURNAL;

ADULT; AGED; FAMILY HEALTH; FEMALE; GENES, P16; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; PEDIGREE; POINT MUTATION; PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF; VARIATION (GENETICS);

EID: 0032217165     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00412.x     Document Type: Article

References (44)

1. Bale SJ, Dracopoli NC, Tucker MA, et al: Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p [published erratum appears in N Engl J Med 324:925, 1991]. N Engl J Med 320:1367-1372, 1989
2. Borg A, Johansson U, Johannsonn O, et al: Novel germline p16 mutation in familial malignant melanoma in Southern Sweden. Cancer Res 56:2497-2500, 1996
3. Cairns P, Mao L, Merlo A, et al: Rates of p16 (MTS1) mutations in primary tumours with 9p21 loss. Nature 265:415-416, 1994
4. Caldas C, Hahn SA, da Costa LT, et al: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27-32, 1994
5. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148-1150, 1992
6. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al: Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 54:6041-6044, 1994
7. ARF and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93:8541-8545, 1996
8. Goldstein A, Dracopoli N, Engelstein M, Frase MC, Clark WH, Tucker MA: Linkage of cutaneous malignant melanoma/dysplastic naevi (CMM/DN) to chromosome 9p and evidence for genetic heterogeneity. Am J Hum Genet 54:489-496, 1994
9. Goldstein AM, Fraser MC, Struewing JP, et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974, 1995
10. Gruis NA, van der Velden PA, Sandkuijl LA, et al: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 10:351-353, 1995
11. INK4B is a potential effector of TGF-beta induced cell cycle arrest. Nature 371:257-261, 1994
12. Harland M, Meloni R, Gruis N, et al: Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061-2067, 1997
13. Holland EA, Beaton SC, Becker TM, et al: Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11:2289-2294, 1995
14. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nature Genet 8:15-21, 1994
15. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994a
16. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22-26, 1994b
17. Koh J, Enders GH, Dynlacht BD, Harlow E: Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510, 1995
18. INK4 CDK inhibitory activity. Int J Cancer 66:249-254, 1996
19. INK4a mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405-412, 1995
20. MacGeoch C, Bishop JA, Bataille V, et al: Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 3:2195-2200, 1994
21. INK4a transcript. Cancer Res 55:2995-2997, 1995
22. Merlo A, Herman JG, Mao L, et al: 5′ CpG island methylation associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1:686-692, 1995
23. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
24. Noncarrow DJ, Palmer JM, Walters NK, et al: Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 53:936-942, 1993
25. Ohta M, Nagai H, Shimizu M, et al: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 54:5269-5272, 1994
26. INK4a in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994
27. Platz A, Hansson J, Mansson-Brahme E, et al: Screening of germline mutations in the CDKN2a and CDKN2b genes in Swedish families with hereditary melanoma. J Natl Cancer Inst 89:697-702, 1997
28. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998
29. INK4a) gene. Hum Genet 101:359-364, 1997
30. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000, 1995
31. INK4a functon. Nature Genet 10:114-116, 1995
32. Reymond A, Brent R: p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 11:1173-1178, 1995
33. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
34. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37, 1996
35. Soufir N, Avril MF, Chompret A, et al: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7:209-216, 1998
36. Stone S, Jiang P, Danayananth P, et al: Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55:2988-2994, 1995a
37. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright LA, Kamb A: Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 11:987-991, 1995b
38. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG: Novel mutations in the p16/CDKN2a binding region of the Cyclin-dependent kinase-4 gene. Cancer Res 58:109-113, 1998
39. Ueki K, Rubio MP, Ramesh V, et al: MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3:1841-1845, 1994
40. Walker GJ, Palmer JM, Walters MK, Noncarrow DJ, Parsons PG, Hayward NK: Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions. Oncogene 9:819-824, 1994
41. Walker GJ, Hussussian CJ, Flores JF, et al: Mutations of the CDKN2/p16 gene in Australian melanoma kindreds. Hum Mol Genet 4:1845-1852, 1995
42. Whelan AJ, Bartsch D, Goodfellow PJ: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor suppressor gene. N Engl J Med 33:975-977, 1995
43. Yang R, Gombart AF, Serrano M, Koeffler H: Mutational effects on the p16-INK4a tumor suppressor protein. Cancer Res 55:2503-2506, 1995
44. INK4a binding domain of CDK4 in familial melanoma. Nature Genet 12:97-99, 1996